Compare KMDA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMDA | ASMB |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 442.9M |
| IPO Year | 2013 | 2010 |
| Metric | KMDA | ASMB |
|---|---|---|
| Price | $8.09 | $26.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $44.20 |
| AVG Volume (30 Days) | 34.7K | ★ 91.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.94 | N/A |
| Revenue Next Year | $9.84 | $638.39 |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $11.42 |
| 52 Week High | $9.35 | $39.71 |
| Indicator | KMDA | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 37.61 |
| Support Level | $7.96 | $23.19 |
| Resistance Level | $8.40 | $27.14 |
| Average True Range (ATR) | 0.17 | 1.44 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 11.75 | 1.47 |
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.